TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06389006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disitamab Vedotin for Injection
Description: 2.0mg/kg, intravenous infusion，D1, every 2 weeks, Every 6 weeks is a treatment cycle. A total of 2 cycles (12 weeks) of treatment are performed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 3.0 mg/kg, intravenous infusion, D1, every 2 weeks, every 6 weeks is a treatment cycle. A total of 2 cycles (12 weeks) of treatment are performed. Sequential therapy 3.0 mg/kg, intravenous infusion, D1, every 2 weeks,every 6 weeks is a treatment cycle. A total of 2 cycles (12 weeks) of treatment are performed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: According to body surface area, 90mg/m2, intravenous infusion, D1, every 3 weeks, Every 6 weeks is a treatment cycle. A total of 12 weeks of treatment are performed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: According to body surface area,600mg/m2, intravenous infusion, D1, every 3 weeks , Every 6 weeks is a treatment cycle. A total of 12 weeks of treatment are performed
Study: NCT05027516

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocephin
Description: Single dose of Rocephine® (= ceftriaxone 1g + lidocaine 35mg) intramuscular injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocephin
Description: Single dose of Rocephine® (= ceftriaxone 1g + lidocaine 35mg) intramuscular injection
Study: NCT05513287

Intervention type: OTHER
Intervention: On the period of covid 19
Description: In 2020 and 2021 covid 19 waves in egypt , the effect of this waves in our anathesia in patient wwho undergo cesarean section

Intervention type: OTHER
Intervention: On the period of covid 19
Description: In 2020 and 2021 covid 19 waves in egypt , the effect of this waves in our anathesia in patient wwho undergo cesarean section
Study: NCT05158413

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High dose
Description: Patients will receive a high dose of sesame paste or flour (1200 mg of sesame protein) mixed with apple mousse (supposing child tolerates apple). For the transparency of the study all patients will receive the same commercially prepared apple product
Study: NCT05027516

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Single dose of Rocephine® (= ceftriaxone 1g + lidocaine 35mg) intramuscular injection + single dose of azithromycin 2g orally
Study: NCT05158413

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low dose
Description: Patients will receive a low dose of sesame paste or flour (300 mg of sesame protein) mixed with apple mousse (supposing child tolerates apple). For the transparency of the study all patients will receive the same commercially prepared apple product
Study: NCT06168240

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual lymphatic drainage. will be applied three days per week for four weeks.
Description: Training will applied 3 days a week, for a total of 4 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual lymphatic drainage. will be applied three days per week for four weeks.
Description: Training will applied 3 days a week, for a total of 4 weeks.
Study: NCT06087133

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: StEP:Prenatal
Description: StEP is a health care-based intervention based on elements of Social Cognitive Theory, in which registered dietitians with additional certified lactation counselor training (RD/CLC) provide individual and group-based support for healthy diet, physical activity, other lifestyle behaviors, stress reduction, and healthy gestational weight gain. StEP:Prenatal will be delivered remotely. There are up to 8 sessions scheduled around the routine prenatal care visits and designed to be offered from the first trimester of pregnancy through delivery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Care
Description: Routine care includes routine prenatal and post-partum primary care visits, on-site WIC services and referrals for additional services as needed (e.g., women with poor weight gain, obesity, or diabetes may be offered additional nutrition visits).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine Care
Description: Routine care includes routine prenatal and post-partum primary care visits, on-site WIC services and referrals for additional services as needed (e.g., women with poor weight gain, obesity, or diabetes may be offered additional nutrition visits).
Study: NCT06250894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1inhibitor
Description: Patients receive 3 cycles of preoperative chemotherapy with Sintilimab（PD-1 inbibitor） and SOX (every 3 weeks), followed by radiotherapy (total dose of 36-40Gy in 18-22 fractions) during cycle 1 of the combination. Radical surgery for gastric cancer will be performed within 4-6 weeks after completion of neoadjuvant treatment, followed by 3-5 cycles of postoperative adjuvant chemotherapy with the SOX regimen.
Study: NCT04717193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rectus Sheath Block with 0.25% bupivicaine with 1:200 000 epinephrine
Description: Bilateral rectus sheath block plus infiltration local anesthetic at incision sites.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local Anesthetic Infiltration with 0.25% bupivicaine with 1:200 000 epinephrine
Description: Infiltration of local anesthetic at incision sites.
Study: NCT05973955

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Insomnia Treatment
Description: The Insomnia Treatment is a version of Cognitive Behavioral Therapy for Insomnia adapted to individuals with hazardous alcohol use. It consists of the standard features of this well-established insomnia treatment in addition to adaptations that focus on alcohol use behaviors and alcohol-related thoughts that may be sleep-interfering as well as the provision of alcohol education material.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Education Control
Description: The Education Control intervention is an educational control that provides psychoeducation related to both sleep and to alcohol use.
Study: NCT06204484

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CAPEOX adjuvant therapy
Description: In MRD-/+ standard therapy groups, patients will receive 3-month CAPEOX therapy, regardless of the MRD status.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CAPEOX adjuvant therapy
Description: In MRD-/+ standard therapy groups, patients will receive 3-month CAPEOX therapy, regardless of the MRD status.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: deferred CAPEOX adjuvant therapy
Description: In MRD-negative deferred adjuvant therapy group, patients won't get the standard CAPEOX adjuvant therapy at first. When MRD negative status turns to positive status, the 3-month CAPEOX therapy will be arranged.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mFOLFOXIRI intensive adjuvant therapy
Description: In the MRD+ intensive standard therapy group, which represents a high risk of recurrence, patients will receive 3-month mFOLFOXIRI intensive therapy, instead of the CAPEOX standard adjuvant therapy.
Study: NCT06594705

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JenaValve Trilogy Heart Valve System
Description: TAVR with JenaValve Trilogy Heart Valve System
Study: NCT05401981

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Story checklist
Description: The story checklist consists of a couple of questions that gives the physician something to keep in mind while visiting the patients.
Study: NCT04812639

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Buccal infiltration technique
Description: a technique for injecting local anesthetic solution in the buccal mucobuccal fold between the roots of the targeted tooth

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inferior alveolar nerve block technique
Description: a technique for injecting local anesthetic solution to anesthetize the inferior alveolar nerve
Study: NCT06245434

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Morphological MRI
Description: Precise description of brain lesion by a 3T MRI within the 1st week after sedation withdrawal

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Assessment of correlation between patients' behaviour and neurophysiological markers of consciousness.
Description: Video recording of spontaneous patients' movements in the bed and synchronized during 2h with high-density EEG.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Assessment of correlation between patients' behaviour and neurophysiological markers of consciousness.
Description: Video recording of spontaneous patients' movements in the bed and synchronized during 2h with high-density EEG.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assessment of correlation between patients' behaviour and neurophysiological markers of consciousness.
Description: Video recording of spontaneous patients' movements in the bed and synchronized during 2h with high-density EEG.
Study: NCT05779930

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19 specific Chimeric Antigen Receptor T Cell
Description: Infusion of CD19 CAR-T Cells manufactured on-site using the CliniMACS Prodigy
Study: NCT06292819

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bright light
Description: Bright light will use a 5000-10,000 Lux LED light source. Exposure is for 60 minutes daily, between 7pm and 9pm.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Near-infrared light
Description: Near-infrared light will use a wavelength of 850nm and a dose range of 1 - 6.5 joules/cm2. It is fixed on the neck with a band, the light source contacts the back of the neck, and is used for 60 minutes before going to bed.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bright light+ near-infrared light
Description: After using the bright light device, then use the near-infrared light device on the back of the neck before going to bed.
Study: NCT06618274

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention of oncology research navigator embedded in central oncology navigation
Description: The intervention of oncology research navigator or Oncology research navigator (ORN) is embedded in central oncology navigation cancer care delivery.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Central oncology navigation (SOC)
Description: Central oncology navigation (SOC ) alone.
Study: NCT06243341

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lepidium meyenii (MACA)
Description: The MACA supplement is derived from a concentrated 6:1 blend of black, red, and yellow MACA root compounds, with an 80:15:5 ratio respectively.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Lepidium meyenii (MACA)
Description: The MACA supplement is derived from a concentrated 6:1 blend of black, red, and yellow MACA root compounds, with an 80:15:5 ratio respectively.
Study: NCT06399731

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-frequency (10Hz) rTMS
Description: High-frequency (10 Hz) rTMS targeting the left DLPFC, based on fMRI-peak activation during performance of the Tower of London task, at 110% resting motor threshold intensity, corrected for scalp-cortex distance at the target location, for a total of 3000 pulses per session, using 30 trains of 10 seconds with 30-second inter-train intervals (total duration: 20 minutes), using neuronavigation to record the pulse location.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-frequency (10Hz) rTMS
Description: High-frequency (10 Hz) rTMS targeting the left DLPFC, based on fMRI-peak activation during performance of the Tower of London task, at 110% resting motor threshold intensity, corrected for scalp-cortex distance at the target location, for a total of 3000 pulses per session, using 30 trains of 10 seconds with 30-second inter-train intervals (total duration: 20 minutes), using neuronavigation to record the pulse location.
Study: NCT06715358

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reintervention
Description: * SI! Program environment intervention from 2nd grade through all Elementary Education.~* SI! Program classroom intervention in 2nd grade.~* SI! Program classroom intervention in 5th grade.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Late intervention
Description: * SI! Program environment intervention from 5th grade through all Elementary Education.~* SI! Program classroom intervention in 5th grade.
Study: NCT06717100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib 150 MG [Ofev]
Description: Nintedanib 150 MG will be administered every 12 hours from Days 1 to 20. LYT-100 will be titrated from 275 MG three times a day on Days 8 to 10, to 550 MG three times a day on Days 11 to 13, to 825 MG three times a day on Days 14 to 30.
Study: NCT06399731

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Description: Anodal high-definition tDCS. The anode will be placed at the F3 EEG location, coordinates registered using neuronavigation on the first intervention session on-site, and cathodes at Fp1, Fz, C3 and F7, in a ring surrounding the anode, using π cm2 circular stimulation electrodes, stimulating the left DLPFC at 2 mA intensity for a duration of 20 minutes, 15 s ramp up and 15 s ramp down. After an initial on-site instructional tDCS session, the tDCS intervention will be delivered at home, in part remotely-supervised via MS Teams.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Description: Anodal high-definition tDCS. The anode will be placed at the F3 EEG location, coordinates registered using neuronavigation on the first intervention session on-site, and cathodes at Fp1, Fz, C3 and F7, in a ring surrounding the anode, using π cm2 circular stimulation electrodes, stimulating the left DLPFC at 2 mA intensity for a duration of 20 minutes, 15 s ramp up and 15 s ramp down. After an initial on-site instructional tDCS session, the tDCS intervention will be delivered at home, in part remotely-supervised via MS Teams.
Study: NCT06717711

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-intensity Extracorporeal Shock Wave Therapy (LiESWT)
Description: LiESWT will be performed with PiezoWave2 from Richard Wolf and ELvation® Medical. In a single session 12,000 shocks with an energy flux density of 0.16 mJ/mm2 will be applied (4,000 over the crura of the penis and 8,000 to the penil shaft). The penis is placed in a dedicated penile holder, stretched, and shockwaves are administered with a linear therapy source (applicator) using the linear shockwave tissue coverage (LSTC-ED®) technique which makes it possible to administer shockwaves homogenously to all of the erectile tissue.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDE5 inhibitor (tadalafil)
Description: Phosphodiesterase-5 (PDE5) inhibitors

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PDE5 inhibitor (tadalafil)
Description: Phosphodiesterase-5 (PDE5) inhibitors
Study: NCT06718322

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Primary Cancer Prevention Implementation Toolkit (PCP-IT)
Description: The PCP-IT is an online implementation support toolkit which aims to support implementation teams in improving the implementation of primary cancer prevention programs (PCPs). The PCP-IT builds upon the theory-base and the proven to be effective ItFits tool. The PCP-IT encompasses a total of six modules which are designed to guide implementers through the process of selecting and adapting PCP programs, identifying and addressing barriers, and developing and applying tailored implementation strategies. The toolkit includes: (1) a repository of PCP programs, (2) a repository of determinants of practice, (3) a repository of implementation strategies, (4) stakeholder consultation at all stages, (5) an online community of implementation practitioners, and (6) structured stepped process flows, instructions, examples and worksheets for working with the materials. https://global.itfits-toolkit.com/
Study: NCT06718751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid 650 MG
Description: PO administration of TXA tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PO administration of placebo tablet
Study: NCT06717607

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low cylinder toric IOL
Description: Clareon T2 toric IOL implantation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: non-toric IOL implantation
Description: Clareon non-toric IOL
Study: NCT06713031

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: cannulated compression screws + iliac bone graft
Description: Using cannulated compression screws + iliac bone graft technique to treat old femoral neck fractures

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DCS + medial support plate + iliac bone graft
Description: Using DCS + medial support plate + iliac bone graft technique to treat old femoral neck fractures
Study: NCT04517435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ME-401
Description: ME-401 (60 mg) will be given by mouth every 21 days for 6 cycles on days 1-4 (dose level 1) OR days 1-7 (dose level 2) of a 21 day cycle. Dose escalation will be performed in a standard 3+3 design

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 IV/subcutaneous rituximab day 1 of 21-day cycle.~First dose of rituximab will be given IV and subsequent doses can be either IV or SQ based on institutional guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 750 mg/m2 IV Cyclophosphamide day 1 of 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 50 mg/m2 IV Doxorubicin day 1 of 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.4 mg/m2 (max 2 mg) IV Vincristine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 100mg PO Prednisone Days 1-5 of 21-day cycle
Study: NCT05638906

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MINT
Description: Mechanical rotation of the Surgical Device is achieved by the rotating system (i.e., Activation Device), which is comprised of: (1) Controller which dictates the activation pulse duration, the rotations per minute (RPM) and the forwards and backwards movement of the micro trephine; (2) Motor; and (3) Footswitch.
Study: NCT06047938

Intervention type: RADIATION
Intervention: ultrasound on carotid
Description: CIT will be assessed using ultrasound evaluation by measuring the intima-media thickness of carotid arteries (IMT). This non-invasive method is used to detect subclinical atherosclerosis and it can be used in a multitude of patients including children\[11\]. It will be carried out on the two study groups (FMF patients and the control group) and the results will be compared. It will be conducted in Assiut University Neurosonology Unit, at the Department of Neurology.
Study: NCT05692635

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI of the Brain
Description: An MRI brain scan with and without gadolinium contrast. Three scans are planned for each participant.
Study: NCT05624268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: COMP360 Psilocybin administered under supportive conditions

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Psilocybin
Description: COMP360 Psilocybin administered under supportive conditions
Study: NCT06399536

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Individualized ANH
Description: Participants will undergo individualized ANH based on the West China Liu's Score after anesthetic induction. The decision of autologous blood transfusion or allogeneic red cell transfusion will be made according to the West China Liu's Score.
Study: NCT05039021

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HARMONIC 1100 Shears
Description: HARMONIC 1100 Shears is used for vessel transection according to instructions for use.
Study: NCT04932941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP1032
Description: Hard gelatin capsules for oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules matched to MP1032 for oral administration.
Study: NCT04224727

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Commitment Contract
Description: A group contract where the primary individual, who will be tracked by the study, can invite peers to join the contract and form their group. To initiate a contract, a user must choose: the stakes, start date, and (for weight loss contracts) target weight, and and, optionally, to allow other members to have the power to invite other people to join the group.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Commitment Contract
Description: A group contract where the primary individual, who will be tracked by the study, can invite peers to join the contract and form their group. To initiate a contract, a user must choose: the stakes, start date, and (for weight loss contracts) target weight, and and, optionally, to allow other members to have the power to invite other people to join the group.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Monetary Rewards
Description: Individuals eligible for a $100 monetary reward (incentive) following verified smoking cessation or weight loss.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Monetary Rewards
Description: Individuals eligible for a $100 monetary reward (incentive) following verified smoking cessation or weight loss.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Commitment Contract
Description: Individuals will have the opportunity to create an individual commitment contract to quit smoking. They will have the option to set the stakes, start date, and (for weight loss contracts) target weight.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Commitment Contract
Description: Individuals will have the opportunity to create an individual commitment contract to quit smoking. They will have the option to set the stakes, start date, and (for weight loss contracts) target weight.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Information
Description: In the initial survey, participants will receive additional information treatments on the likelihood of success of the different incentives and contracts, with the goal of shifting naives to sophisticates.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Information
Description: In the initial survey, participants will receive additional information treatments on the likelihood of success of the different incentives and contracts, with the goal of shifting naives to sophisticates.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Information
Description: In the initial survey, participants will receive additional information treatments on the likelihood of success of the different incentives and contracts, with the goal of shifting naives to sophisticates.